Guardian Pharmacy Services - GRDN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: -12.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.00
▲ +0.35 (1.42%)

This chart shows the closing price for GRDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardian Pharmacy Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRDN

Analyst Price Target is $22.00
▼ -12.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Guardian Pharmacy Services in the last 3 months. The average price target is $22.00, with a high forecast of $24.00 and a low forecast of $21.00. The average price target represents a -12.00% upside from the last price of $25.00.

This chart shows the closing price for GRDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Guardian Pharmacy Services.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Truist FinancialBoost TargetBuy ➝ Buy$22.00 ➝ $24.00
10/22/2024StephensInitiated CoverageOverweight$21.00
10/21/2024Raymond JamesInitiated CoverageOutperform$21.00
10/21/2024Truist FinancialInitiated CoverageBuy$22.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/8/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Read More

Today's Range

Now: $25.00
Low: $24.05
High: $25.28

50 Day Range

MA: $20.04
Low: $16.80
High: $25.03

52 Week Range

Now: $25.00
Low: $14.16
High: $25.57

Volume

228,703 shs

Average Volume

163,142 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardian Pharmacy Services?

The following Wall Street sell-side analysts have issued reports on Guardian Pharmacy Services in the last year: Raymond James, Stephens, and Truist Financial Co..
View the latest analyst ratings for GRDN.

What is the current price target for Guardian Pharmacy Services?

0 Wall Street analysts have set twelve-month price targets for Guardian Pharmacy Services in the last year. Their average twelve-month price target is $22.00, suggesting a possible downside of 12.0%. Truist Financial Co. has the highest price target set, predicting GRDN will reach $24.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $21.00 for Guardian Pharmacy Services in the next year.
View the latest price targets for GRDN.

What is the current consensus analyst rating for Guardian Pharmacy Services?

Guardian Pharmacy Services currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRDN will outperform the market and that investors should add to their positions of Guardian Pharmacy Services.
View the latest ratings for GRDN.

What other companies compete with Guardian Pharmacy Services?

How do I contact Guardian Pharmacy Services' investor relations team?

Guardian Pharmacy Services' physical mailing address is 300 Galleria Parkway SE, Suite 800, Atlanta, GA 30339, United States. The company's listed phone number is (404) 810-0089 and its investor relations email address is [email protected]. The official website for Guardian Pharmacy Services is guardianpharmacy.com. Learn More about contacing Guardian Pharmacy Services investor relations.